CA2206471A1 - Fragments d'anticorps monoclonaux possedant une activite immunodepressive - Google Patents

Fragments d'anticorps monoclonaux possedant une activite immunodepressive

Info

Publication number
CA2206471A1
CA2206471A1 CA002206471A CA2206471A CA2206471A1 CA 2206471 A1 CA2206471 A1 CA 2206471A1 CA 002206471 A CA002206471 A CA 002206471A CA 2206471 A CA2206471 A CA 2206471A CA 2206471 A1 CA2206471 A1 CA 2206471A1
Authority
CA
Canada
Prior art keywords
fab fragment
mab
fab
cells
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002206471A
Other languages
English (en)
Inventor
Damir Vidovic
Zoltan Nagy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2206471A1 publication Critical patent/CA2206471A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur des fragments mAb monovalents (Fab) de mAb qui sont capables de d'atténuer l'expression HLA-DR sur les cellules présentatrices de l'antigène, Les fragments FAB peuvent atténuer cette expression de HLA-DR sans la toxicité des fragments mAb apparentés ou de fragments bivalents (F(ab)'2) du mAb. Les fragments Fab de l'invention sont donc des composés immunosuppresseurs spécifiques du CMH de classe II qui n'ont pas d'effets secondaires cytotoxiques.
CA002206471A 1994-12-07 1995-11-25 Fragments d'anticorps monoclonaux possedant une activite immunodepressive Abandoned CA2206471A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35091594A 1994-12-07 1994-12-07
US08/350,915 1994-12-07

Publications (1)

Publication Number Publication Date
CA2206471A1 true CA2206471A1 (fr) 1996-06-13

Family

ID=23378740

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002206471A Abandoned CA2206471A1 (fr) 1994-12-07 1995-11-25 Fragments d'anticorps monoclonaux possedant une activite immunodepressive

Country Status (19)

Country Link
EP (1) EP0787151A1 (fr)
JP (1) JP2001506122A (fr)
CN (1) CN1168679A (fr)
AR (1) AR002005A1 (fr)
AU (1) AU4256096A (fr)
BR (1) BR9509902A (fr)
CA (1) CA2206471A1 (fr)
CO (1) CO4480041A1 (fr)
CZ (1) CZ172497A3 (fr)
FI (1) FI972430A0 (fr)
HU (1) HUT77342A (fr)
IL (1) IL116228A0 (fr)
MA (1) MA23739A1 (fr)
NO (1) NO972522L (fr)
PE (1) PE52996A1 (fr)
PL (1) PL320610A1 (fr)
TR (1) TR199501542A2 (fr)
WO (1) WO1996017874A1 (fr)
ZA (1) ZA9510195B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893507A1 (fr) * 1997-07-25 1999-01-27 Institut Gustave Roussy Utilisation de ligands de MHC classe II (CD4 et LAG-3) comme adjuvants pour la vaccination de LAG-3 dans le traitement du cancer
AU5588099A (en) 1998-08-28 2000-03-21 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
US7521047B2 (en) 2000-05-12 2009-04-21 Gpc Biotech Ag Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
EP1156062A1 (fr) * 2000-05-12 2001-11-21 GPC Biotech AG Peptides/protéines immunomodulants et liants à un antigène du CMH classe II humain
ATE365749T1 (de) * 2000-05-12 2007-07-15 Gpc Biotech Ag Humane peptide/proteine, die das töten von zellen,einschliesslich lymphoide tumorzellen, herbeiführen oder bewirken
US20030096285A1 (en) 2001-10-11 2003-05-22 Tso J. Yun Identifying anti-tumor targets or agents by lipid raft immunization and proteomics
KR20050036852A (ko) 2001-10-15 2005-04-20 기린 비루 가부시키가이샤 항-ｈｌａ-ｄｒ 항체
CA2571710A1 (fr) 2004-06-24 2006-11-02 Nicholas Valiante Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
US20110243841A1 (en) * 2010-04-01 2011-10-06 Immunomedics, Inc. Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells
KR102647825B1 (ko) * 2021-07-22 2024-03-14 서울대학교산학협력단 항-hla-dp 단클론 항체 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3269354D1 (en) * 1981-06-25 1986-04-03 Univ Leland Stanford Junior Allele specific immunotherapeutic method and dosage form
CA2070182C (fr) * 1989-12-27 2002-12-24 John Ghrayeb Immunoglobuline chimerique pour recepteurs cda
SK285046B6 (sk) * 1991-07-25 2006-05-04 Idec Pharmaceuticals Corporation Chimérna protilátka, ktorá sa špecificky viaže na ľudský antigén, farmaceutický prostriedok s jej obsahom, spôsob jej výroby a použitie

Also Published As

Publication number Publication date
EP0787151A1 (fr) 1997-08-06
WO1996017874A1 (fr) 1996-06-13
TR199501542A2 (tr) 1996-07-21
NO972522L (no) 1997-08-06
CZ172497A3 (en) 1997-10-15
HUT77342A (hu) 1998-03-30
AU4256096A (en) 1996-06-26
CO4480041A1 (es) 1997-07-09
JP2001506122A (ja) 2001-05-15
MA23739A1 (fr) 1996-07-01
NO972522D0 (no) 1997-06-03
PL320610A1 (en) 1997-10-13
BR9509902A (pt) 1997-10-21
FI972430A (fi) 1997-06-06
AR002005A1 (es) 1998-01-07
CN1168679A (zh) 1997-12-24
FI972430A0 (fi) 1997-06-06
MX9704225A (es) 1997-09-30
ZA9510195B (en) 1996-06-07
IL116228A0 (en) 1996-03-31
PE52996A1 (es) 1996-12-12

Similar Documents

Publication Publication Date Title
Reinherz et al. Antibody directed at a surface structure inhibits cytolytic but not suppressor function of human T lymphocytes
US5885573A (en) Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US7034121B2 (en) Antibodies against CTLA4
US6491916B1 (en) Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
RU2192281C2 (ru) Способы и композиции для иммуномодуляции
US5948893A (en) Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody
US20060292142A1 (en) Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
EP0603735A2 (fr) Anticorps monoclonaux qui déterminent un antigène unique du complèxe de récepteurs antigènes sur les B-cellules humaines
CN109563169A (zh) 抗hla-g特异性抗体
KR20180085793A (ko) 글리코실화된 pd-1에 대해 특이적인 항체 및 이의 사용 방법
WO1994028027A9 (fr) Procedes et matieres de modulation de l'activite immunodepressive et de la toxicite d'anticorps monoclonaux
JPH09509053A (ja) Ｔ−細胞抗原、並びにｔ−細胞介在状態の診断及び処理へのそれらの使用
KR19990022650A (ko) 사람 ｂ7.1 및/또는 ｂ7.2 영장류화된 형태에 특이적인 원숭이 단일클론성 항체 및 이의 약제학적 조성물
IL113617A (en) Use of LAG-3 antibodies to prepare a therapeutic agent that stimulates the immune system
KR20150082316A (ko) 새로운 항원 결합 단백질들 및 암의 치료를 위한 어드레싱 산물로서 그들의 용도
LT4225B (en) Immuno-stimulatory monoclonal antibodies
CA2206471A1 (fr) Fragments d'anticorps monoclonaux possedant une activite immunodepressive
Liu et al. CD11b is a novel alternate receptor for CD154 during alloimmunity
JP2003533219A (ja) 免疫毒素融合タンパク質及びその発現法
AU2004240180B2 (en) Methods of prolonged suppression of humoral immunity
Huet et al. Role in T-cell activation for HLA class I molecules from accessory cells: further distinction between activation signals delivered to T cells via CD2 and CD3 molecules.
US20070092506A1 (en) Use of rapamycin and agents that inhibit B7 activity in immunomodulation
US7531168B2 (en) Method for downmodulating immune response in type I diabetes
JPH05503687A (ja) 自己免疫疾患の治療
JPH07242566A (ja) 免疫抑制剤

Legal Events

Date Code Title Description
FZDE Discontinued